D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.23 MYR
Market Cap: 1.2B MYR
Have any thoughts about
Duopharma Biotech Bhd?
Write Note

Duopharma Biotech Bhd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Duopharma Biotech Bhd
Total Receivables Peer Comparison

Comparables:
P
PLABS
A
AHEALTH
R
RHONEMA
Y
YSPSAH
K
KOTRA

Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Total Receivables
myr249.2m
CAGR 3-Years
15%
CAGR 5-Years
6%
CAGR 10-Years
20%
P
PeterLabs Holdings Bhd
KLSE:PLABS
Total Receivables
myr39.3m
CAGR 3-Years
-5%
CAGR 5-Years
9%
CAGR 10-Years
8%
A
Apex Healthcare Bhd
KLSE:AHEALTH
Total Receivables
myr194.5m
CAGR 3-Years
9%
CAGR 5-Years
4%
CAGR 10-Years
6%
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Total Receivables
myr38m
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Total Receivables
myr69.4m
CAGR 3-Years
-4%
CAGR 5-Years
-4%
CAGR 10-Years
2%
K
Kotra Industries Bhd
KLSE:KOTRA
Total Receivables
myr36m
CAGR 3-Years
13%
CAGR 5-Years
1%
CAGR 10-Years
-3%

See Also

What is Duopharma Biotech Bhd's Total Receivables?
Total Receivables
249.2m MYR

Based on the financial report for Jun 30, 2024, Duopharma Biotech Bhd's Total Receivables amounts to 249.2m MYR.

What is Duopharma Biotech Bhd's Total Receivables growth rate?
Total Receivables CAGR 10Y
20%

Over the last year, the Total Receivables growth was 34%. The average annual Total Receivables growth rates for Duopharma Biotech Bhd have been 15% over the past three years , 6% over the past five years , and 20% over the past ten years .

Back to Top